Twist Bioscience Corporation (NASDAQ:TWST – Get Free Report)’s stock price reached a new 52-week high during trading on Tuesday . The company traded as high as $148.81 and last traded at $149.1050, with a volume of 72068 shares traded. The stock had previously closed at $140.80.
Wall Street Analysts Forecast Growth
TWST has been the topic of several research analyst reports. Leerink Partners set a $110.00 price target on Twist Bioscience in a report on Thursday, July 16th. Piper Sandler lifted their price objective on Twist Bioscience from $85.00 to $115.00 and gave the stock an “overweight” rating in a report on Wednesday, August 5th. Barclays upped their price objective on Twist Bioscience from $65.00 to $95.00 and gave the company an “overweight” rating in a research report on Wednesday, June 24th. Guggenheim reissued a “buy” rating on shares of Twist Bioscience in a research report on Monday. Finally, UBS Group set a $89.00 target price on Twist Bioscience in a research report on Monday, June 15th. Eight analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $98.30.
View Our Latest Stock Analysis on TWST
Twist Bioscience Stock Performance
Twist Bioscience (NASDAQ:TWST – Get Free Report) last announced its earnings results on Monday, August 3rd. The company reported ($0.56) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.05). The company had revenue of $118.38 million during the quarter, compared to the consensus estimate of $114.55 million. Twist Bioscience had a negative return on equity of 28.64% and a negative net margin of 31.66%.Twist Bioscience’s revenue for the quarter was up 23.2% compared to the same quarter last year. During the same period in the prior year, the business posted $0.33 earnings per share. As a group, sell-side analysts expect that Twist Bioscience Corporation will post -2.12 earnings per share for the current fiscal year.
Insider Buying and Selling
In other news, SVP Paula Green sold 291 shares of Twist Bioscience stock in a transaction dated Monday, June 22nd. The stock was sold at an average price of $87.32, for a total transaction of $25,410.12. Following the transaction, the senior vice president directly owned 120,414 shares of the company’s stock, valued at $10,514,550.48. The trade was a 0.24% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Adam Laponis sold 2,399 shares of the business’s stock in a transaction that occurred on Thursday, July 9th. The shares were sold at an average price of $94.33, for a total value of $226,297.67. Following the transaction, the chief financial officer owned 110,276 shares of the company’s stock, valued at approximately $10,402,335.08. This trade represents a 2.13% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 151,529 shares of company stock worth $17,708,772 over the last ninety days. 3.08% of the stock is owned by corporate insiders.
Hedge Funds Weigh In On Twist Bioscience
A number of hedge funds have recently modified their holdings of the company. E. Ohman J or Asset Management AB bought a new stake in Twist Bioscience during the second quarter valued at about $853,000. UBS Group AG lifted its position in shares of Twist Bioscience by 28.6% in the fourth quarter. UBS Group AG now owns 662,317 shares of the company’s stock valued at $21,009,000 after acquiring an additional 147,389 shares in the last quarter. Allspring Global Investments Holdings LLC bought a new position in shares of Twist Bioscience in the first quarter worth about $22,563,000. Bank of America Corp DE boosted its stake in shares of Twist Bioscience by 46.3% in the first quarter. Bank of America Corp DE now owns 584,261 shares of the company’s stock worth $27,764,000 after acquiring an additional 184,907 shares during the period. Finally, Pictet Asset Management Holding SA grew its position in shares of Twist Bioscience by 108.5% during the fourth quarter. Pictet Asset Management Holding SA now owns 222,647 shares of the company’s stock worth $7,302,000 after purchasing an additional 115,880 shares in the last quarter.
Twist Bioscience Company Profile
Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.
At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.
Featured Stories
- Five stocks we like better than Twist Bioscience
- Williams-Sonoma’s Quarter Gave Bulls More Than Just a Beat-and-Raise
- Alcoa’s Gallium Project Opens a New Door Beyond Aluminum
- Oura’s $16 Billion IPO Could Put a New Price on Wearable Tech
- Can Tesla’s Flying Roadster Distract From Its Real Risks?
Receive News & Ratings for Twist Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Twist Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
